Home 2023

Sanofi

Conscious Re-Coupling: M&A Comes Back Surely, If Slowly
Bioprocessing

Conscious Re-Coupling: M&A Comes Back Surely, If Slowly

Alex Philippidis -
0
Sanofi, Scribe Launch Up-to-$1.2B Collaboration in SCD, Genomic Diseases
Genome Editing

Sanofi, Scribe Launch Up-to-$1.2B Collaboration in SCD, Genomic Diseases

Alex Philippidis -
0
Modular Bioprocessing Lines Help Biopharma Cut Costs
Bioprocessing

Modular Bioprocessing Lines Help Biopharma Cut Costs

Christina Jackson -
0
Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration
Genome Editing

Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration

Alex Philippidis -
0
Revolutionizing Monoclonal Antibody Production Monitoring
Bioprocessing

Revolutionizing Monoclonal Antibody Production Monitoring

John Sterling -
0
Sanofi Funds New Delivery Technology for RNA Vaccines and Therapies to the Tune of $25 Million
News

Sanofi Funds New Delivery Technology for RNA Vaccines and Therapies to the Tune of $25 Million

John Sterling -
0
StockWatch: COPD Data, Analysts, Treg Cell Therapy Deal Lift Regeneron
GEN Edge

StockWatch: COPD Data, Analysts, Treg Cell Therapy Deal Lift Regeneron

Alex Philippidis -
0
Sanofi Extends Deal with CytoReason to License IBD Disease Modeling
Drug Discovery

Sanofi Extends Deal with CytoReason to License IBD Disease Modeling

Jonathan D Grinstein, PhD -
0
NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno-Oncology Programs
Drug Discovery

NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno-Oncology Programs

Jonathan D Grinstein, PhD -
1
Olema Plans Pivotal Trial for Two-Prong Breast Cancer Treatment
Cancer

Olema Plans Pivotal Trial for Two-Prong Breast Cancer Treatment

Alex Philippidis -
0
123...32Page 1 of 32
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.